AR108939A1 - Sistema de administración transdérmica que contiene metilfenidato o sus sales, y métodos de este - Google Patents
Sistema de administración transdérmica que contiene metilfenidato o sus sales, y métodos de esteInfo
- Publication number
- AR108939A1 AR108939A1 ARP170101831A ARP170101831A AR108939A1 AR 108939 A1 AR108939 A1 AR 108939A1 AR P170101831 A ARP170101831 A AR P170101831A AR P170101831 A ARP170101831 A AR P170101831A AR 108939 A1 AR108939 A1 AR 108939A1
- Authority
- AR
- Argentina
- Prior art keywords
- delivery system
- transdermal delivery
- methylphenidate
- methods
- transdermal administration
- Prior art date
Links
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 title abstract 4
- 229960001344 methylphenidate Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000010410 layer Substances 0.000 abstract 5
- 230000037317 transdermal delivery Effects 0.000 abstract 5
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 3
- 229920001971 elastomer Polymers 0.000 abstract 3
- 239000005060 rubber Substances 0.000 abstract 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000013464 silicone adhesive Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000001012 protector Effects 0.000 abstract 1
- 229920003048 styrene butadiene rubber Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D153/00—Coating compositions based on block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Coating compositions based on derivatives of such polymers
- C09D153/02—Vinyl aromatic monomers and conjugated dienes
- C09D153/025—Vinyl aromatic monomers and conjugated dienes modified
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Materials Engineering (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polymers & Plastics (AREA)
Abstract
Un sistema de administración transdérmica que comprende metilfenidato o su sal como ingrediente activo. También métodos para administrar una cantidad terapéuticamente eficaz de metilfenidato a un sujeto para el tratamiento de una condición patológica. Esta condición patológica incluye una afección neurológica, tal como el trastorno por déficit de atención (ADD) y/o el trastorno por déficit de atención con hiperactividad (ADHD). También kits que incluyen el sistema de administración transdérmica y métodos para fabricar y usar el sistema de administración transdérmica. Reivindicación 1: Un sistema de administración transdérmica que comprende: (i) una capa adhesiva de silicona; y (ii) una capa con matriz que contiene el fármaco que comprende: (a) metilfenidato o su sal aceptable desde el punto de vista farmacéutico; y (b) un polímero a base de caucho, que comprende un mejorador de la pegajosidad sintético hidrogenado, en donde el sistema de administración transdérmica tiene una velocidad de flujo que varía de alrededor de 6 mg/cm²/h a 100 mg/cm²/h, entre 2 - 18 horas después del inicio del tratamiento. Reivindicación 2: El sistema de administración transdérmica de acuerdo con la reivindicación 1, en donde el polímero a base de caucho es caucho de copolímero en bloque de estireno-butadieno. Reivindicación 3: El sistema de administración transdérmica de acuerdo con cualquiera de las reivindicaciones anteriores, que consiste esencialmente de una capa de soporte, la capa adhesiva de silicona, la capa con matriz que contiene el fármaco y un protector antiadherente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357316P | 2016-06-30 | 2016-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108939A1 true AR108939A1 (es) | 2018-10-10 |
Family
ID=60787668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101831A AR108939A1 (es) | 2016-06-30 | 2017-06-30 | Sistema de administración transdérmica que contiene metilfenidato o sus sales, y métodos de este |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9980921B2 (es) |
| EP (1) | EP3448778B1 (es) |
| JP (1) | JP7005539B2 (es) |
| KR (1) | KR20190039692A (es) |
| CN (1) | CN109689527B (es) |
| AR (1) | AR108939A1 (es) |
| TW (1) | TW201803563A (es) |
| WO (1) | WO2018005593A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9980921B2 (en) * | 2016-06-30 | 2018-05-29 | Taho Pharmaceuticals Ltd. | Transdermal delivery system containing methylphenidate or its salts and methods thereof |
| AU2020380376A1 (en) * | 2019-11-07 | 2022-06-02 | Amyris, Inc. | Compositions and methods for delivering cannabinoids to skin |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6210705B1 (en) * | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| US20020102291A1 (en) | 1997-12-15 | 2002-08-01 | Noven Pharmaceuticals, Inc. | Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| WO2005009417A1 (en) | 2003-07-21 | 2005-02-03 | Noven Pharmaceuticals, Inc. | Composition and method for controlling grug delivery from silicone adhesive blends |
| US20060078602A1 (en) | 2004-10-08 | 2006-04-13 | Noven Pharmaceuticals, Inc. | Device for transdermal administration of drugs including acrylic polymers |
| TWI389709B (zh) * | 2005-12-01 | 2013-03-21 | Novartis Ag | 經皮治療系統 |
| CN102548545A (zh) * | 2009-08-18 | 2012-07-04 | 道康宁公司 | 多层透皮贴剂 |
| CN102630160B (zh) * | 2009-09-16 | 2014-05-07 | 株式会社三养生物制药 | 透皮递送系统、其制备方法以及使用所述系统的透皮递送方法 |
| US20110200663A1 (en) | 2010-02-12 | 2011-08-18 | Nitto Denko Corporation | Methylphenidate patch preparation |
| US9072682B2 (en) * | 2012-12-31 | 2015-07-07 | Mylan Inc. | Transdermal dosage form for low-melting point active agent |
| WO2014159573A1 (en) * | 2013-03-14 | 2014-10-02 | Noven Pharmaceuticals, Inc | Methylphenidate transdermal compositions with rubber-based adhesives |
| US9682068B2 (en) | 2013-05-20 | 2017-06-20 | Mylan Inc. | Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders |
| ES2733812T3 (es) | 2014-07-31 | 2019-12-03 | Noven Pharma | Polímeros acrílicos que contienen silicona para composiciones de administración transdérmica de fármacos |
| US9980921B2 (en) * | 2016-06-30 | 2018-05-29 | Taho Pharmaceuticals Ltd. | Transdermal delivery system containing methylphenidate or its salts and methods thereof |
-
2017
- 2017-06-27 US US15/634,188 patent/US9980921B2/en active Active
- 2017-06-28 CN CN201780040626.7A patent/CN109689527B/zh active Active
- 2017-06-28 JP JP2018569164A patent/JP7005539B2/ja active Active
- 2017-06-28 EP EP17821115.7A patent/EP3448778B1/en active Active
- 2017-06-28 WO PCT/US2017/039650 patent/WO2018005593A1/en not_active Ceased
- 2017-06-28 KR KR1020197002175A patent/KR20190039692A/ko not_active Ceased
- 2017-06-30 TW TW106122005A patent/TW201803563A/zh unknown
- 2017-06-30 AR ARP170101831A patent/AR108939A1/es unknown
-
2018
- 2018-04-24 US US15/961,112 patent/US10537532B2/en active Active
- 2018-04-24 US US15/961,335 patent/US10420733B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190039692A (ko) | 2019-04-15 |
| US20180263923A1 (en) | 2018-09-20 |
| TW201803563A (zh) | 2018-02-01 |
| CN109689527B (zh) | 2021-02-19 |
| EP3448778A1 (en) | 2019-03-06 |
| CN109689527A (zh) | 2019-04-26 |
| US20180000746A1 (en) | 2018-01-04 |
| US10420733B2 (en) | 2019-09-24 |
| EP3448778A4 (en) | 2020-01-08 |
| EP3448778B1 (en) | 2025-05-28 |
| US20180263922A1 (en) | 2018-09-20 |
| JP7005539B2 (ja) | 2022-02-04 |
| WO2018005593A1 (en) | 2018-01-04 |
| US9980921B2 (en) | 2018-05-29 |
| US10537532B2 (en) | 2020-01-21 |
| JP2019524698A (ja) | 2019-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019007389A (es) | Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno. | |
| MX2017012321A (es) | Parche de microagujas para administrar un ingrediente activo a la piel. | |
| CY1122575T1 (el) | Φαρμακοτεχνικες μορφες διστρωματικου δισκιου | |
| CY1120283T1 (el) | Διαδερμικο θεραπευτικο συστημα για την χορηγηση ριβαστιγμινης ή παραγωγων αυτης | |
| MX2019001103A (es) | Sistema de suministro transdermico de donepezilo. | |
| MX2023007853A (es) | Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo. | |
| AR093481A1 (es) | Parche de varios dias para la administracion transdermica de rotigotina | |
| PH12015501169A1 (en) | Transdermal delivery system | |
| BR112015024271A2 (pt) | sistema de fornecimento transdérmico | |
| MX366230B (es) | Composiciones multipolimericas para liberación transdermica de farmaco. | |
| AR070031A1 (es) | Sistemas de administracion transdermicos de droga ketotifen y metodos para el tratamiento de enfermedades oftalmicas | |
| AR072492A1 (es) | Dispositivo y administracion transdermica de estrogeno | |
| CR9737A (es) | Dispositivos de administracion transdermicas de farmacos que contienen o-desmetilvenlafaxina (odv) sus sales. | |
| MX2019001104A (es) | Sistemas de suministro transdermico de memantina. | |
| MX2016008138A (es) | Sistema para el suministro transdermico de ingredientes activos. | |
| CO6640335A2 (es) | Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes | |
| AR093118A1 (es) | Composiciones y metodos para la administracion transdermica de anfetamina | |
| MX2012002727A (es) | Sistema terapeutico transdermico para administrar fentanilo o un analogo del mismo. | |
| UA114101C2 (xx) | Трансдермальна терапевтична система для введення фентанілу або його аналога | |
| BR112014004635A2 (pt) | sistema terapêutico transdérmico para cloridrato de ácido 5-aminolavulínico | |
| AR108939A1 (es) | Sistema de administración transdérmica que contiene metilfenidato o sus sales, y métodos de este | |
| DOP2014000171A (es) | Sistema para la administración de fármacos | |
| BR112022012111A2 (pt) | Sistema terapêutico transdérmico contendo agomelatina | |
| MX2021012709A (es) | Sistema terapeutico transdermico. | |
| CO2019008657A2 (es) | Composición intranasal que comprende betahistina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |